Kraan 1988.

Methods	Setting: The Netherlands, hospital outpatient clinic Randomisation: yes, method not stated Allocation concealment: unclear Design: parallel group Length of intervention period: 8 weeks Masking: double blind Excluded: not stated Withdrawals: stated (none) Baseline Characteristics: significant difference between groups for FEV1 Jadad score: 3
Participants	30 adults: 22M 8F Age range: 18‐37 years Inclusion criteria: History of episodic wheezing Strongly positive skin tests for at least two common allergens including house dust mite Mild symptoms are controlled by bronchodilators or prophylactic drugs (cromolyn sodium or inhaled steroids) FEV1 (% predicted) 70 or greater Methacholine bronchial responsiveness (PC20 FEV1) less than 8 mg/ml Exclusion criteria: Regular use of oral steroids Baseline asthma control Symptom frequency: symptoms controlled FEV1 (% predicted): range 76‐108
Interventions	1. BUD 50 mcg 2 puffs 2xdaily (200mcg/day) via MDI 2. BUD 200 micrograms 2 puffs 2xdaily (800 mcg/day) via MDI
Outcomes	FEV1 (% predicted) Methacholine bronchial responsiveness (PC20 FEV1) Clinic assessed asthma symptom score Blood eosinophil count Withdrawal due to asthma exacerbation
Notes	No reply from author to clarify details of randomisation method.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear